ERAS-601
RAS/MAPK-altered solid tumors
Phase 1Active
Key Facts
About Erasca
Erasca, founded in 2018, is a public, clinical-stage biotech on a mission to 'erase cancer' by targeting the RAS/MAPK pathway, the most commonly mutated signaling cascade in cancer, affecting ~5.5 million new patients annually. The company has built a broad pipeline of small molecules, large molecules, and protein degraders targeting the pathway at multiple nodes. Led by a seasoned team with a track record in precision oncology, Erasca is strategically advancing combination regimens to overcome resistance and improve outcomes for patients with high-unmet-need cancers.
View full company profile